[go: up one dir, main page]

PE20030907A1 - Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa - Google Patents

Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa

Info

Publication number
PE20030907A1
PE20030907A1 PE2003000205A PE2003000205A PE20030907A1 PE 20030907 A1 PE20030907 A1 PE 20030907A1 PE 2003000205 A PE2003000205 A PE 2003000205A PE 2003000205 A PE2003000205 A PE 2003000205A PE 20030907 A1 PE20030907 A1 PE 20030907A1
Authority
PE
Peru
Prior art keywords
alkyl
formyl
amino
transferase
methyl
Prior art date
Application number
PE2003000205A
Other languages
English (en)
Inventor
Laura Anne Bloom
Theodore James Boritzki
Leslie Ann Kuhn
Luke Raymond Zhender
Jerry Jialum Meng
Richard Charles Ogden
Donald James Skalitzky
Pei-Pei Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030907A1 publication Critical patent/PE20030907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A UN METODO PARA DESTRUIR CELULAS DEFICIENTES EN METILTIOADENOSINA-FOSFORILASA (MTAP) QUE COMPRENDE ADMINISTRAR a)INHIBIDOR DE GLICINAMIDA-RIBONUCLEOTIDO-FORMILTRANSFERASA, AMINOIMIDAZOLCARBOXIMIDA-RIBONUCLEOTIDO-FORMILTRANSFERASA DE FORMULA A (ACIDO N-(5-[2-(2-AMINO-4(3H)-OXO-5,6,7,8-TETRAHIDROPIRIDO[2,3-d]-PIRIMIDIN-6-IL)-(R)-ETIL]-4-METILTIENO-2-IL)-L-GLUTAMICO, O UN COMPUESTO OXOPIRIDO DE FORMULA II; A ES S, Se; GRUPO ES UN INTERCALADOR NO CICLICO; ANILLO ES CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO; R1 Y R2 SON H, ALQUILO, GRUPO HIDROLIZABLE; R3 ES H, ALQUILO, CICLOALQUILO; b)UN AGENTE ANTITOXICO (ANALOGO DE METILADENOSINA FOSFORILASA) EN UNA CANTIDAD PARA INCREMENTAR LA DOSIS TOLERADA MAXIMA DEL INHIBIDOR DE FORMULA X; DONDE R41 ES Rg, RgYRhRi, CONRjRk, COORh; Rg ES ALQUILO, ALQUENILENO, ALQUINILENO; Y ES O, NH, S, METILENO; Rh, Ri SON H, ALQUILO, ALQUENILO, ALQUINILO; Rj Y Rk SON H, ALQUILO, AMINO, HALOALQUILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS (2S,3R,4R,5R)-5-(6-AMINO-9H-PURIN-9-IL)-4-(METILTIO)-2-[(METIL-TIO)METIL]TETRAHIDROFURAN-3-OL; (2S,3S,4R,5R)-2-(6-AMINO-9H-PURIN-9-IL)-5-{[(4-CLOROBENCIL)TIO]-METIL}-TETRAHIDROFURAN-3,4-DIOL, ENTRE OTROS
PE2003000205A 2002-03-04 2003-02-28 Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa PE20030907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36164502P 2002-03-04 2002-03-04
US43227502P 2002-12-09 2002-12-09

Publications (1)

Publication Number Publication Date
PE20030907A1 true PE20030907A1 (es) 2003-10-29

Family

ID=27791683

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000205A PE20030907A1 (es) 2002-03-04 2003-02-28 Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa

Country Status (14)

Country Link
US (1) US20040043959A1 (es)
EP (1) EP1482977A1 (es)
KR (1) KR20040091089A (es)
AR (1) AR038863A1 (es)
AU (1) AU2003206019A1 (es)
BR (1) BR0308222A (es)
CA (1) CA2477422A1 (es)
IL (1) IL163776A0 (es)
NO (1) NO20044191L (es)
PA (1) PA8568201A1 (es)
PE (1) PE20030907A1 (es)
TW (1) TW200304380A (es)
UY (1) UY27692A1 (es)
WO (1) WO2003074083A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
JP2005292087A (ja) * 2004-04-05 2005-10-20 Shionogi & Co Ltd ５’−デオキシ−５’−メチルチオアデノシンに対する抗体
US7981902B2 (en) * 2006-06-28 2011-07-19 Duquesne University Of The Holy Ghost Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US9725479B2 (en) * 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103339139A (zh) 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
DK2646444T3 (da) 2010-12-03 2016-06-27 Epizyme Inc Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
US20140357594A1 (en) * 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9175032B2 (en) 2013-03-15 2015-11-03 Epizyme, Inc. Methods of synthesizing substituted purine compounds
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA39986A (fr) * 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016056606A1 (ja) * 2014-10-07 2016-04-14 国立大学法人京都大学 ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AU2017230658B2 (en) * 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
UA123637C2 (uk) 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
WO2018050684A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
SI3512857T1 (sl) 2016-09-14 2021-07-30 Janssen Pharmaceutica Nv Spiro biciklični zaviralci interakcije menin-MLL
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MA46341A (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
AU2018225312B2 (en) 2017-02-27 2024-02-08 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
MA51004A (fr) 2017-12-08 2020-10-14 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN109111445B (zh) * 2018-11-02 2020-12-18 哈尔滨商业大学 5’-呋喃甲酰酯-3’-脱氧腺苷的合成方法及应用
CN109369758B (zh) * 2018-11-02 2021-04-13 哈尔滨商业大学 5′-(6-氯烟酰酯)-3′-脱氧腺苷的合成方法及其应用
US20220160747A1 (en) * 2019-03-20 2022-05-26 Korea Research Institute Of Chemical Technology Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
MX2021015363A (es) 2019-06-12 2022-04-06 Janssen Pharmaceutica Nv Intermedios espirobicíclicos novedosos.
MX2022007652A (es) 2019-12-19 2022-09-23 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal.
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori
EP4326273A4 (en) * 2021-04-19 2025-04-23 Emory University QUINAZOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES ASSOCIATED WITH NOX INHIBITION
CN113603721B (zh) * 2021-06-21 2023-12-01 重庆文理学院 一种合成saicar的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
US5945427A (en) * 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
WO1994013295A1 (en) * 1992-12-16 1994-06-23 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
RU2127275C1 (ru) * 1993-01-29 1999-03-10 Агурон Фармасьютикалз, Инк. 2-[4-[2-(2-амино-4-оксо-4,6,7,8-тетрагидро-3h-пиримидо[5,4-b] [1,4]тиазин-6- ил)этил] бензоил(или тиенилкарбонил)амино]пентандиовая кислота или ее низший алкиловый эфир, способ ингибирования роста и пролиферации клеток и способ ингибирования фермента
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5840505A (en) * 1993-12-29 1998-11-24 The Regents Of The University Of California Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells
US5942393A (en) * 1993-12-29 1999-08-24 The Regents Of The University Of California Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
DE69432801T2 (de) * 1994-07-28 2003-12-04 Agouron Pharmaceuticals, Inc. Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind

Also Published As

Publication number Publication date
AR038863A1 (es) 2005-02-02
NO20044191L (no) 2004-09-30
KR20040091089A (ko) 2004-10-27
WO2003074083A1 (en) 2003-09-12
PA8568201A1 (es) 2003-11-12
EP1482977A1 (en) 2004-12-08
CA2477422A1 (en) 2003-09-12
BR0308222A (pt) 2005-02-09
UY27692A1 (es) 2003-10-31
AU2003206019A1 (en) 2003-09-16
TW200304380A (en) 2003-10-01
IL163776A0 (en) 2005-12-18
US20040043959A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
PE20030907A1 (es) Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa
PE131699A1 (es) Inhibidores de aminotiazol de cinasas dependientes de ciclina
BR9509686A (pt) Biaribultírico saturado ou ácidos 5-biaripentanóicos e derivados como inibidores de matrizes metaloproteases
RU2004130426A (ru) Циклические амиды
US20050222222A1 (en) Pyrrolidine compounds
EA199800909A1 (ru) Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
AR065389A2 (es) Composicion farmaceutica para disminuir la hiperglucemia y para profilaxis y tratamiento de la diabetes
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
HRP20120706T1 (hr) Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
RU2015119640A (ru) Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
PE20040974A1 (es) Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que los contienen y procedimientos para su preparacion
AR061873A1 (es) Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas.
HRP20120440T1 (hr) Inhibitori virusa hepatitisa c
JP2010500413A5 (es)
JP2015535252A5 (es)
CA2485850A1 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
JO2239B1 (en) Method for preparing benzothophen derivatives
BR0016424A (pt) Inibidores de n-[5-[[[5-alquiil-2-oxazolil]metil]-tio]-2-tiazolil]carbox amida de cinases dependentes de ciclina
AR029145A1 (es) Compuesto de hidroxamato pirrolidina sustituida, inhibidores de metaloproteasa, composicion farmaceutica que lo comprende y uso para elaborar una composicion farmaceutica
PT97631A (pt) Processo de preparacao de compostos inibidores de renina,incluindo (2s)-2-benzil-3-(1-metilpiperazin-4-ilsufonil)propionil-(l)-(4-tiazolil)-ala-amida de ( 2r,3r,4s)-2-amino-1-ciclo-hexil-3,4-di-hidroxi-6-metil-heptano e seus analogos, e de composicoes farmaceuticas
AR048691A1 (es) Compuestos con estructura de alquino con accion antagonista de mch y medicamentos que contienen estos compuestos
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks

Legal Events

Date Code Title Description
FA Abandonment or withdrawal